1984
DOI: 10.1002/macp.1984.021850201
|View full text |Cite
|
Sign up to set email alerts
|

Polymers containing enzymatically degradable bonds, 9. Chymotrypsm catalyzed hydrolysis of a p‐nitroanilide drug model, p bound via oligopeptides onto poly(vinylpyrrolidone‐co‐maleic anhydride)

Abstract: Copolymers of I-vinyl-2-pyrrolidone with maleic anhydride which contain oligopeptide sidechains with L-phenylalanine p-nitroanilide (Phe-NAP) end groups were synthesized. The chymotrypsin catalyzed hydrolysis of these polymers was studied. The rate of p-nitroaniline release was found to depend on the structure of the oligopeptide sequences: -Gly-Gly-Val-Phe-NAp > --Gly-Val-Phe-NAp > -Gly-Gly-Phe-NAP. From a comparison with similar substrates based on poly[N-(2-hydroxypropyl)methacrylamide] the influence of the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

1985
1985
2015
2015

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 25 publications
(12 citation statements)
references
References 30 publications
0
12
0
Order By: Relevance
“…PVP oligomers terminated with ester groups are intermediates for the preparation of end-carboxylated PVP amenable to coupling reactions with hydroxylated or aminated compounds. For instance, they may be used for grafting proteins 2) and for preparing oligomeric prodrugs 7) , as well as PVP-grafted polysaccharides and other hydroxylated natural polymers.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…PVP oligomers terminated with ester groups are intermediates for the preparation of end-carboxylated PVP amenable to coupling reactions with hydroxylated or aminated compounds. For instance, they may be used for grafting proteins 2) and for preparing oligomeric prodrugs 7) , as well as PVP-grafted polysaccharides and other hydroxylated natural polymers.…”
Section: Discussionmentioning
confidence: 99%
“…However, in contrast to proteins, PVP is physiologically inactive which has led to its use as a blood plasma substitute or blood volume expander 5) , although these applications are now very much restricted since it is not metabolized or in any way degraded in the body. Moreover, PVP was the first synthetic polymer to be used for the modification of therapeutically useful enzymes 6) and it has been proposed as a soluble drug carrier 7,8) .…”
Section: Introductionmentioning
confidence: 99%
“…6,27 This was attributed to the higher steric hindrance for the access of the enzyme to the oligopeptide substrate in high MW polymers. 28 Another point to be considered is the MW threshold for the elimination of macromolecules via glomerular filtration, which is ϳ 50 kDa.…”
Section: Oligo(bis-tyrhcl-peg 6 Kda-sebacate) (Oligomerization)mentioning
confidence: 97%
“…PVP has also been proposed for the modification of therapeutically useful enzymes [21] and as a soluble drug carrier. [22,23] Communication: x-Hydroxy-functionalized oligo(Nvinyl-2-pyrrolidinone) (PVPOH) was prepared by chaintransfer radical polymerization in the presence of 2-isopropoxyethanol as the chain-transfer agent, and grafted onto dextran. Two PVP-Dex graft copolymers were obtained starting from different PVPOH/dextran weight ratios in the feed, namely 2 : 1 and 5 : 1.…”
Section: Introductionmentioning
confidence: 99%
“…[24 -27] The synthetic method applied was the radical polymerization of VP in the presence of functionalized chain-transfer agents (CTA) with small chain-transfer constants, thus facilitating molecular weight control. [21,22] Using this technique, both x-hydroxy-, x-lactone-and x-ester-functionalized VP oligomers were prepared. These VP oligomers are endowed with wide synthetic potential, e. g. in the synthesis of graft-copolymers.…”
Section: Introductionmentioning
confidence: 99%